Comparison of High-Dose Chemotherapy + Rituximab and CHOP + Rituximab in High-Risk Follicular Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00435955

Recruitment Status : Unknown

Verified February 2007 by Azienda Ospedaliera San Giovanni Battista.
Recruitment status was: Active, not recruiting

First Posted : February 16, 2007

Last Update Posted : February 16, 2007

Sponsor:

Collaborators:

University of Turin, Italy

Gruppo Italiano Trapianto di Midollo Osseo

Gruppo Italiano Studio Linfomi

Hoffmann-La Roche

Information provided by:

Azienda Ospedaliera San Giovanni Battista

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Unknown
Primary Completion Date :	No date given
Study Completion Date :	No date given

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, Rambaldi A, Pulsoni A, Musso M, Liberati AM, Olivieri A, Gallamini A, Pogliani E, Rota Scalabrini D, Callea V, Di Raimondo F, Pavone V, Tucci A, Cortelazzo S, Levis A, Boccadoro M, Majolino I, Pileri A, Gianni AM, Passera R, Corradini P, Tarella C; Gruppo Italiano Trapianto di Midollo Osseo (GITMO); Intergruppo Italiano Linfomi (IIL). Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood. 2008 Apr 15;111(8):4004-13. doi: 10.1182/blood-2007-10-116749. Epub 2008 Jan 31.

To Top